2022
An Acute Exacerbation of Idiopathic Pulmonary Fibrosis After BNT162b2 mRNA COVID-19 Vaccination A Case Report
Ghincea A, Ryu C, Herzog EL. An Acute Exacerbation of Idiopathic Pulmonary Fibrosis After BNT162b2 mRNA COVID-19 Vaccination A Case Report. CHEST Journal 2022, 161: e71-e73. PMID: 35131075, PMCID: PMC8814523, DOI: 10.1016/j.chest.2021.07.2160.Peer-Reviewed Case Reports and Technical NotesConceptsIdiopathic pulmonary fibrosisAE-IPFAcute exacerbationPulmonary fibrosisLung diseaseCase reportFatal interstitial lung diseaseMRNA COVID-19 vaccinationChronic lung diseaseInterstitial lung diseaseVaccine-preventable diseasesNovel case reportA Case ReportCOVID-19 vaccinationScar tissue formationRespiratory decompensationAdverse eventsPulmonary embolismVulnerable patientsDrug toxicityPotential associationShort courseDiseaseExacerbationFibrosis
2020
Serum mitochondrial DNA predicts the risk of acute exacerbation and progression of idiopathic pulmonary fibrosis
Sakamoto K, Furukawa T, Yamano Y, Kataoka K, Teramachi R, Walia A, Suzuki A, Inoue M, Nakahara Y, Ryu C, Hashimoto N, Kondoh Y. Serum mitochondrial DNA predicts the risk of acute exacerbation and progression of idiopathic pulmonary fibrosis. European Respiratory Journal 2020, 57: 2001346. PMID: 32855220, PMCID: PMC8177039, DOI: 10.1183/13993003.01346-2020.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisAcute exacerbationPulmonary fibrosisDisease progressionFatal interstitial lung diseaseInterstitial lung diseaseSerum mitochondrial DNAAccepted biomarkersClinical deteriorationMedian survivalDeadly complicationDisease courseLethal complicationLung functionLung diseaseUnknown etiologyExacerbationUnmet needProgressionComplicationsRapid deteriorationPatientsFibrosisDevastating diseaseDisease